The Food and Drug Administration (FDA) has approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with previously untreated chronic ...

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

Researchers evaluated the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a potential treatment for obstructive sleep apnea in patients with obesity.

Chronic pain was most common patient-reported qualifying condition, accounting for 64.5 and 31.9% in 2016 and 2024.

The Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve (Edward Lifesciences) for pediatric patients with congenital heart ...

Polypharmacy involving prescription medications affected more than one-third of older adults in 2021 to 2023, according to a ...

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

The oral ALK2 inhibitor significantly reduced mean total new heterotopic ossification volume at 24 weeks in patients aged 12 ...